Growth momentum Fortis Life Sciences is expanding its portfolio and capabilities with recent launches such as AbNano VHH anti-NK cell library and ongoing collaborations, indicating a strong opportunity to cross-sell specialized reagents, discovery services, and turnkey manufacturing for NK cell and complex receptor targeting programs.

Strategic partnerships Active collaborations with Astraea Bio and engagement with Deliver Bio through grants signal a customer-focused ecosystem. Leverage these relationships to offer integrated spatial biology, multi-omics, and targeted delivery solutions to similar research partners seeking end-to-end support from discovery to manufacturing.

End-to-end capabilities Fortis presents a full-stack offering from in-house reagents to GMP and ISO 13485 manufacturing across multiple facilities. This positions the company to win multi-phase programs that need seamless transition from validation and scale-up to compliant manufacturing, appealing to diagnostics and therapeutics developers.

Competitive differentiation The portfolio includes high-sensitivity LFA kits with AuNPs and a broad set of brands (Abcore, Arista Biologicals, Vector Biolabs, etc.), enabling combined solutions for rapid assay development, translational studies, and custom reagent sourcing for customers upgrading from traditional suppliers.

Global expansion signals Global customer base with four R&D sites and three manufacturing facilities, plus recent news coverage and funding activity, suggests a growing international demand. This creates a sales opportunity to target biopharma and diagnostics companies expanding R&D footprints or near-shoring manufacturing to Fortis’s compliant facilities.